Does immune checkpoint inhibitor therapy increase the frequency of adverse reactions to concomitant medications?

被引：7

作者：

Hammond, Sean ^{[1
,2
]}

Olsson-Brown, Anna ^{[1
]}

Grice, Sophie ^{[1
]}

Naisbitt, Dean J. ^{[1
]}

机构：

[1] Univ Liverpool, Ctr Drug Safety Sci, Dept Mol & Clin Pharmacol, Ashton St, Liverpool L69 3GE, Merseyside, England

[2] Alderley Pk, ApconiX, Alderley Edge, England

来源：

CLINICAL AND EXPERIMENTAL ALLERGY | 2022年 / 52卷 / 05期

关键词：

D O I：

10.1111/cea.14134

中图分类号：

R392 [医学免疫学];

学科分类号：

100102 ;

摘要：

[No abstract available]

引用

页码：600 / 603

页数：4

共 10 条

[1] Case of Fatal Immune-Related Skin Toxicity From Sequential Use of Osimertinib After Pembrolizumab: Lessons for Drug Sequencing in Never-Smoking Non-Small-Cell Lung Cancer [J].

Cui, Wanyuan ;

Cotter, Chantal ;

Sreter, Katherina Bernadette ;

Heelan, Kara ;

Creamer, Daniel ;

Basu, Tanya N. ;

Handy, Jonathan ;

Walsh, Sarah ;

Popat, Sanjay .

JCO ONCOLOGY PRACTICE, 2020, 16 (12) :842-+

[2] Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors [J].

Das, Satya ;

Johnson, Douglas B. .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7 (01)

[3] High proportion of drug hypersensitivity reactions to sulfasalazine following its use in anti-PD-1-associated inflammatory arthritis [J].

Ford, Mark ;

Sahbudin, Ilfita ;

Filer, Andrew ;

Steven, Neil ;

Fisher, Benjamin A. .

RHEUMATOLOGY, 2018, 57 (12) :2244-2246

[4] Negative Regulation by PD-L1 during Drug-Specific Priming of IL-22-Secreting T Cells and the Influence of PD-1 on Effector T Cell Function [J].

Gibson, Andrew ;

Ogese, Monday ;

Sullivan, Andrew ;

Wang, Eryi ;

Saide, Katy ;

Whitaker, Paul ;

Peckham, Daniel ;

Faulkner, Lee ;

Park, B. Kevin ;

Naisbitt, Dean J. .

JOURNAL OF IMMUNOLOGY, 2014, 192 (06) :2611-2621

[5]

Griffin Liezel L, 2018, JAAD Case Rep, V4, P229, DOI 10.1016/j.jdcr.2017.09.028

[6] T cell mediated hypersensitivity to previously tolerated iodinated contrast media precipitated by introduction of atezolizumab [J].

Hammond, Sean ;

Olsson-Brown, Anna ;

Gardner, Joshua ;

Thomson, Paul ;

Ali, Serat-E ;

Jolly, Carol ;

Carr, Dan ;

Ressel, Lorenzo ;

Pirmohamed, Munir ;

Naisbitt, Dean .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (05)

[7] T-Cell Activation by Low Molecular Weight Drugs and Factors That Influence Susceptibility to Drug Hypersensitivity [J].

Hammond, Sean ;

Thomson, Paul J. ;

Ogese, Monday O. ;

Naisbitt, Dean J. .

CHEMICAL RESEARCH IN TOXICOLOGY, 2020, 33 (01) :77-94

[8] Treatment of PD-1-/- Mice With Amodiaquine and Anti-CTLA4 Leads to Liver Injury Similar to Idiosyncratic Liver Injury in Patients [J].

Metushi, Imir G. ;

Hayes, M. Anthony ;

Uetrecht, Jack .

HEPATOLOGY, 2015, 61 (04) :1332-1342

[9] Immune-related adverse events of checkpoint inhibitors [J].

Ramos-Casals, Manuel ;

Brahmer, Julie R. ;

Callahan, Margaret K. ;

Flores-Chavez, Alejandro ;

Keegan, Niamh ;

Khamashta, Munther A. ;

Lambotte, Olivier ;

Marlette, Xavier ;

Prat, Aleix ;

Suarez-Almazor, Maria E. .

NATURE REVIEWS DISEASE PRIMERS, 2020, 6 (01)

[10] Phase II study of the immune-checkpoint inhibitor ipilimumab plus dacarbazine in Japanese patients with previously untreated, unresectable or metastatic melanoma [J].

Yamazaki, N. ;

Uhara, H. ;

Fukushima, S. ;

Uchi, H. ;

Shibagaki, N. ;

Kiyohara, Y. ;

Tsutsumida, A. ;

Namikawa, K. ;

Okuyama, R. ;

Otsuka, Y. ;

Tokudome, T. .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 76 (05) :969-975

← 1 →